For example, cognitive decline affects 70% of PD patients with pathogenic alpha-synuclein (SNCA) gene variants, while only 23% of Leucine-Rich Repeat Kinase 2 (LRRK2) carriers exhibit cognitive impairment (18). This evidence concerns the gene LRRK2 and Parkinson disease.